{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2Fe2b093f3-a645-444b-98ab-5cff27e26243","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/e2b093f3-a645-444b-98ab-5cff27e26243\"></iframe>","title":"Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer","description":"\n        <p>Dr Neal Shore from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and Dr Mary-Ellen Taplin from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the current and future management of high-risk, hormone-sensitive nonmetastatic prostate cancer, moderated by Dr Neil Love. Produced by Research To Practice.</p>\n\n<p>CME information and select publications <a href=\"https://researchtopractice.com/InsideTheIssue2023/HigherRiskProstate\" rel=\"nofollow\">here</a></p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/e7e96b00-8ba3-4a9b-886b-fc468f61e27b/cover.jpg"}